Open AccessCost benefit analysis of sexually transmitted diseases 1
Author(s) -
Bulut Ayşen
Publication year - 1999
Publication title -
fems immunology & medical microbiology
Language(s) - English
Resource type - Journals
eISSN - 1574-695X
pISSN - 0928-8244
DOI - 10.1111/j.1574-695x.1999.tb01319.x
Subject(s) - psychological intervention , intervention (counseling) , cost–benefit analysis , cost effectiveness analysis , developing country , sexually transmitted disease , economic cost , environmental health , resource allocation , medicine , cost effectiveness , risk analysis (engineering) , family medicine , economic growth , biology , economics , human immunodeficiency virus (hiv) , nursing , syphilis , ecology , neoclassical economics , market economy
Suggested measures to prevent transmission and sequelae of sexually transmitted diseases are almost universally agreed. But the important question to be answered is whether the interventions are worth the resources spent. To facilitate the decision making on resource allocation, the best possible information should be available concerning the relationships between health intervention programs and changes in the health status. Cost benefit analysis is the main approach used to assess the efficiency of any intervention. If the economic benefits of the program are greater than the costs, the program should be seriously considered. Although information about the costs of management of STDs is scarce in developing countries because of the complicated behavioral, social and economic issues involved, it is widely held that making treatment available for curable sexually transmitted diseases represents one of the most cost‐effective ways to improve the health in the world.